Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PHGE Stock Forecast 2025-2026
$0.52
Current Price
$12.88M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to PHGE Price Targets
+3,969.8%
To High Target of $21.00
+3,485.3%
To Median Target of $18.50
+3,000.8%
To Low Target of $16.00
PHGE Price Momentum
-10.3%
1 Week Change
-3.7%
1 Month Change
-85.4%
1 Year Change
-28.8%
Year-to-Date Change
-89.5%
From 52W High of $4.90
+8.2%
From 52W Low of $0.48
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching BiomX (PHGE) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on PHGE and similar high-potential opportunities.
Latest PHGE Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, PHGE has a bullish consensus with a median price target of $18.50 (ranging from $16.00 to $21.00). Currently trading at $0.52, the median forecast implies a 3,485.3% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Joseph Pantginis at HC Wainwright & Co., projecting a 3,969.8% upside. Conversely, the most conservative target is provided by Keay Nakae at Chardan Capital, suggesting a 3,000.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PHGE Analyst Ratings
2
Buy
0
Hold
0
Sell
PHGE Price Target Range
Low
$16.00
Average
$18.50
High
$21.00
Current: $0.52
Latest PHGE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PHGE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 4, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $21.00 |
| Apr 1, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $21.00 |
| Jan 10, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $2.00 |
| Jan 8, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $2.00 |
| Aug 16, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $2.00 |
| May 28, 2024 | Laidlaw & Co. | Yale Jen | Buy | Initiates | $2.50 |
| May 21, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $2.00 |
| Apr 22, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $2.00 |
| Apr 3, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $2.00 |
| Mar 7, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $2.00 |
| Nov 14, 2023 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $7.00 |
| Aug 9, 2023 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $7.00 |
| May 15, 2023 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $7.00 |
| Nov 10, 2022 | Chardan Capital | Keay Nakae | Buy | Maintains | $2.00 |
| May 24, 2022 | Chardan Capital | Keay Nakae | Buy | Maintains | $6.00 |
| May 12, 2022 | Ladenburg Thalmann | Michael Higgins | Buy | Maintains | $8.00 |
| Nov 16, 2021 | Chardan Capital | Keay Nakae | Buy | Maintains | $13.00 |
| Oct 19, 2021 | Chardan Capital | Keay Nakae | Buy | Maintains | $16.00 |
| Oct 18, 2021 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $10.00 |
| Apr 15, 2021 | Ladenburg Thalmann | Buy | Initiates | $0.00 |
BiomX Inc. (PHGE) Competitors
The following stocks are similar to BiomX based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
BiomX Inc. (PHGE) Financial Data
BiomX Inc. has a market capitalization of $12.88M with a P/E ratio of -0.4x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -130.2%.
Valuation Metrics
Market Cap
$12.88M
Enterprise Value
$24.26M
P/E Ratio
-0.4x
PEG Ratio
0.0x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+130.8%
Current Ratio
2.5x
Debt/Equity
39.7x
ROE
-130.2%
ROA
-65.1%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
BiomX Inc. (PHGE) Business Model
About BiomX Inc.
What They Do
Develops phage-based microbiome therapies.
Business Model
BiomX Inc. operates as a clinical-stage biotechnology company that monetizes its proprietary phage technology to develop innovative treatments for diseases associated with microbiome imbalances. The company focuses on creating customizable therapies by leveraging its platform for rapid identification of bacterial targets and corresponding phages, which can lead to partnerships and licensing agreements with pharmaceutical companies.
Additional Information
BiomX is positioned at the cutting edge of addressing antibiotic-resistant bacteria, a pressing issue in healthcare. Their work has significant implications for the pharmaceutical industry and contributes to advancements in precision medicine and sustainable healthcare solutions, attracting interest from investors and potential collaborators.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
52
CEO
Mr. Jonathan Eitan Solomon MBA
Country
Israel
IPO Year
N/A
Website
www.biomx.comBiomX Inc. (PHGE) Latest News & Analysis
Latest News
BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025
3 days ago
Quick Summary
BiomX Inc. (NYSE American: PHGE) will hold a conference call and webcast on May 15, 2025, at 2:00 p.m. ET to discuss Q1 2025 financial results and updates on its programs.
Why It Matters
BiomX's upcoming conference call will reveal Q1 2025 financial results and updates on its phage therapy advancements, influencing investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
BiomX (PHGE) shows a hammer chart pattern, suggesting support after recent losses, along with rising earnings estimate revisions, indicating a potential trend reversal.
Why It Matters
BiomX's hammer pattern suggests potential price stabilization, while rising earnings estimates indicate improving sentiment, signaling a possible trend reversal that could attract buyers.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
The Company will hold a conference call today at 9:00 AM ET and a KOL event on April 3, 2025, at 11:00 AM ET to discuss results.
Why It Matters
The conference call and KOL event indicate upcoming insights into the company's performance and strategy, potentially influencing stock valuation and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
BiomX Inc. reported a going concern qualification from its auditor in its annual report for FY 2024, filed on March 25, 2025, to comply with NYSE American disclosure requirements.
Why It Matters
The going concern qualification indicates potential financial instability for BiomX, raising concerns about its ability to continue operations, which can negatively impact investor confidence and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates
1 month ago
Quick Summary
BiomX Inc. reported its financial results for Q4 and the full year 2024, focusing on its development of phage therapies targeting pathogenic bacteria.
Why It Matters
BiomX's financial results and updates on phage therapies indicate its growth potential and innovation in treating bacterial infections, which could impact stock performance and investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
BiomX Inc. (NYSE American: PHGE) will release its Q4 and full year 2024 financial results and updates on March 25, 2025.
Why It Matters
BiomX's upcoming financial results and updates may impact investor sentiment on its growth trajectory and the potential success of its phage therapies, influencing stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PHGE Stock
What is BiomX Inc.'s (PHGE) stock forecast for 2025?
Based on our analysis of 5 Wall Street analysts, BiomX Inc. (PHGE) has a median price target of $18.50. The highest price target is $21.00 and the lowest is $16.00.
Is PHGE stock a good investment in 2025?
According to current analyst ratings, PHGE has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.52. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PHGE stock?
Wall Street analysts predict PHGE stock could reach $18.50 in the next 12 months. This represents a 3,485.3% increase from the current price of $0.52. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is BiomX Inc.'s business model?
BiomX Inc. operates as a clinical-stage biotechnology company that monetizes its proprietary phage technology to develop innovative treatments for diseases associated with microbiome imbalances. The company focuses on creating customizable therapies by leveraging its platform for rapid identification of bacterial targets and corresponding phages, which can lead to partnerships and licensing agreements with pharmaceutical companies.
What is the highest forecasted price for PHGE BiomX Inc.?
The highest price target for PHGE is $21.00 from Joseph Pantginis at HC Wainwright & Co., which represents a 3,969.8% increase from the current price of $0.52.
What is the lowest forecasted price for PHGE BiomX Inc.?
The lowest price target for PHGE is $16.00 from Keay Nakae at Chardan Capital, which represents a 3,000.8% increase from the current price of $0.52.
What is the overall PHGE consensus from analysts for BiomX Inc.?
The overall analyst consensus for PHGE is bullish. Out of 5 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $18.50.
How accurate are PHGE stock price projections?
Stock price projections, including those for BiomX Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 12, 2025 4:42 AM UTC